{"id":831,"date":"2022-04-28T15:47:00","date_gmt":"2022-04-28T22:47:00","guid":{"rendered":"https:\/\/hightidetx.com\/?p=831"},"modified":"2024-12-24T16:38:52","modified_gmt":"2024-12-24T08:38:52","slug":"hightide-therapeutics-announces-first-patient-dosed-in-phase-2-clinical-study-evaluating-htd1801-in-type-2-diabetes-mellitus","status":"publish","type":"post","link":"https:\/\/www.hightidetx.com\/cn\/2022\/04\/28\/hightide-therapeutics-announces-first-patient-dosed-in-phase-2-clinical-study-evaluating-htd1801-in-type-2-diabetes-mellitus\/","title":{"rendered":"\u541b\u5723\u6cf0HTD1801\u6cbb\u75972\u578b\u7cd6\u5c3f\u75c5\u7684\u4e34\u5e8aII\u671f\u8bd5\u9a8c\u9996\u4f4d\u60a3\u8005\u6210\u529f\u5165\u7ec4"},"content":{"rendered":"\n<p>2022\u5e744\u670828\u65e5\uff0c\u4e2d\u56fd\u6df1\u5733\u3001\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u2014\u2014\u541b\u5723\u6cf0\uff08HighTide Therapeutics Inc.\uff09\u5ba3\u5e03\uff0cHTD1801\u6cbb\u75972\u578b\u7cd6\u5c3f\u75c5\uff08T2DM\uff09\u7684\u4e34\u5e8aII\u671f\u8bd5\u9a8c\u8fd1\u65e5\u5728\u4e2d\u56fd\u6210\u529f\u5b8c\u6210\u9996\u4f4d\u60a3\u8005\u5165\u7ec4\u3002<\/p>\n\n\n\n<p>\u672c\u9879\u591a\u4e2d\u5fc3\u3001\u968f\u673a\u3001\u53cc\u76f2\u3001\u5b89\u6170\u5242\u5e73\u884c\u5bf9\u7167\u7684\u4e34\u5e8aII\u671f\u7814\u7a76\u65e8\u5728\u8bc4\u4f30HTD1801\u5728T2DM\u6210\u4eba\u60a3\u8005\u4e2d\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\uff0c\u5e76\u5c06\u91cd\u70b9\u5173\u6ce8HTD1801\u5bf9\u5408\u5e76\u975e\u9152\u7cbe\u6027\u8102\u80aa\u6027\u809d\u75c5\uff08NAFLD\uff0c\u4fd7\u79f0\u201c\u8102\u80aa\u809d\u201d\uff09\u7684T2DM\u60a3\u8005\u7684\u6cbb\u7597\u4f5c\u7528\u3002\u8bd5\u9a8c\u8ba1\u5212\u5165\u7ec499\u4f8b\u53d7\u8bd5\u8005\uff0c\u9996\u8981\u7ec8\u70b9\u4e3a\u6cbb\u759712\u5468\u540e\u3001\u4e0e\u57fa\u7ebf\u76f8\u6bd4\u7684\u7cd6\u5316\u8840\u7ea2\u86cb\u767d\uff08HbA1c\uff09\u53d8\u5316\u503c\uff1b\u6b21\u8981\u7ec8\u70b9\u5305\u62ec\u8102\u80aa\u809d\u3001\u809d\u529f\u80fd\u3001\u8840\u8102\u7b49\u751f\u7269\u6807\u5fd7\u7269\u7684\u53d8\u5316\u3002<\/p>\n\n\n\n<p>\u541b\u5723\u6cf0\u521b\u59cb\u4eba\u517c\u9996\u5e2d\u6267\u884c\u5b98\u5218\u5229\u5e73\u535a\u58eb\u8868\u793a\uff1a\u201cHTD1801\u72ec\u7279\u7684\u5206\u5b50\u8bbe\u8ba1\u4f7f\u5176\u5177\u6709\u591a\u91cd\u6cbb\u7597\u6548\u679c\uff0c\u6bd4\u5982\uff0c\u6b64\u524d\u5728\u7f8e\u56fd\u5b8c\u6210\u7684\u975e\u9152\u7cbe\u6027\u8102\u80aa\u6027\u809d\u708e\u5408\u5e762\u578b\u7cd6\u5c3f\u75c5\uff08NASH+T2DM\uff09\u7684\u4e34\u5e8aII\u671f\u8bd5\u9a8c\u7ed3\u679c\u663e\u793a\u62a4\u809d\u3001\u964d\u7cd6\u3001\u51cf\u91cd\u3001\u7efc\u5408\u6027\u4ee3\u8c22\u6539\u5584\u3001\u6f5c\u5728\u5fc3\u8840\u7ba1\u83b7\u76ca\u7b49\u79ef\u6781\u6f5c\u529b\u3002\u6211\u4eec\u975e\u5e38\u671f\u5f85\u5728\u4e2d\u56fd\u5f00\u5c55\u7684\u9488\u5bf9T2DM\u7684\u4e34\u5e8aII\u671f\u8bd5\u9a8c\u987a\u5229\u63a8\u8fdb\uff0c\u65e9\u65e5\u4e3aT2DM\u60a3\u8005\uff08\u5c24\u5176\u662fT2DM+NAFLD\u60a3\u8005\uff09\u63d0\u4f9b\u5b89\u5168\u3001\u6709\u6548\u3001\u7efc\u5408\u83b7\u76ca\u7684\u6cbb\u7597\u65b9\u6848\u3002\u201d<\/p>\n\n\n\n<p><strong>\u5173\u4e8e2\u578b\u7cd6\u5c3f\u75c5\u5408\u5e76\u975e\u9152\u7cbe\u6027\u8102\u80aa\u6027\u809d\u75c5\uff08T2DM+NAFLD\uff09<\/strong><\/p>\n\n\n\n<p>T2DM\u548cNAFLD\u5747\u4e3a\u5168\u7403\u6700\u5e38\u89c1\u6162\u6027\u75c5\uff08\u60a3\u75c5\u7387\u5206\u522b\u4e3a9.3%\u548c25%\u5de6\u53f3\uff09\uff0c\u4e14\u4e24\u8005\u4e4b\u95f4\u4e92\u4e3a\u56e0\u679c\u3001\u4e92\u76f8\u6076\u5316\uff0c\u5bfc\u81f4\u60a3\u75c5\u4eba\u7fa4\u9ad8\u5ea6\u91cd\u5408\uff08\u7ea6\u4e00\u534aT2DM\u60a3\u8005\u540c\u65f6\u7f79\u60a3NAFLD\uff1b\u4ec5\u4e2d\u56fd\u4e00\u5730\u7684T2DM+NAFLD\u5408\u5e76\u60a3\u8005\u5c31\u8d85\u8fc77,000\u4e07\u4eba\uff09\u3002<\/p>\n\n\n\n<p>T2DM\u4e0eNAFLD\u7684\u53cc\u5411\u4e92\u52a8\u53e0\u52a0\u4e24\u8005\u4e0e\u5404\u81ea\u81f4\u75c5\u673a\u5236\u3001\u8fdb\u5c55\u673a\u5236\u4e4b\u95f4\u7684\u590d\u6742\u7f51\u72b6\u5173\u7cfb\uff0c\u5bfc\u81f4T2DM+NAFLD\u6bd4\u5355\u7eafT2DM\u6216\u5355\u7eafNAFLD\u7684\u6076\u6027\u7a0b\u5ea6\u66f4\u9ad8\u3001\u9884\u540e\u66f4\u5dee\u2014\u2014\u4f8b\u5982\uff0c\u8840\u7cd6\u63a7\u5236\u66f4\u96be\u8fbe\u6807\u3001\u66f4\u5bb9\u6613\u8fdb\u5c55\u5230\u809d\u75c5\u91cd\u75c7\uff08\u5982NASH\u3001\u809d\u786c\u5316\u3001\u809d\u764c\uff09\u3001\u8bf1\u53d1\u81f4\u547d\u5e76\u53d1\u75c7\u7684\u98ce\u9669\u66f4\u5927\uff08\u5982\u5fc3\u8840\u7ba1\u75be\u75c5\u3001\u80be\u75c5\uff09\u3001\u6b7b\u4ea1\u98ce\u9669\u66f4\u9ad8\u3002\u9488\u5bf9T2DM+NAFLD\u7684\u6cbb\u7597\uff0c\u76ee\u524d\u4e34\u5e8a\u4e0a\u5df2\u666e\u904d\u8ba4\u8bc6\u5230\uff0c\u9700\u8981\u5728\u63a7\u5236\u8840\u7cd6\u7684\u57fa\u7840\u4e0a\u4fdd\u62a4\u809d\u810f\u3001\u7efc\u5408\u6027\u964d\u4f4e\u5fc3\u8840\u7ba1\u4ee3\u8c22\u98ce\u9669\uff0c\u5b9e\u73b0\u201c\u7cd6\u809d\u5171\u6cbb\u201d\u3002<\/p>\n\n\n\n<p>\u57fa\u4e8e\u201c\u8ffd\u6c42\u60a3\u8005\u7684\u7efc\u5408\u83b7\u76ca\u201d\u7684\u5f00\u53d1\u7406\u5ff5\uff0c\u541b\u5723\u6cf0\u8bbe\u8ba1\u3001\u5f00\u53d1\u7684\u591a\u529f\u80fd\u65b0\u5206\u5b50\u5b9e\u4f53HTD1801\u76f4\u51fbT2DM\u548cNAFLD\u7684\u4ee3\u8c22\u6839\u6e90\uff0c\u5b9e\u73b0\u60a3\u8005\u5728\u8840\u7cd6\u3001\u809d\u810f\u3001\u5fc3\u8840\u7ba1\u7b49\u65b9\u9762\u7684\u7efc\u5408\u83b7\u76ca\uff0c\u5e76\u5177\u6709\u826f\u597d\u7684\u5b89\u5168\u6027\u3002\u901a\u8fc7\u7cfb\u7edf\u6027\u534f\u540c\u6cbb\u7597\uff0c\u516c\u53f8\u671f\u5f85\u4e3aT2DM+NAFLD\u60a3\u8005\u63d0\u4f9b\u5b89\u5168\u3001\u6709\u6548\u7684\u89e3\u51b3\u65b9\u6848\uff0c\u6210\u4e3aT2DM+NAFLD\u6cbb\u7597\u7684\u57fa\u7840\u7528\u836f\u3002<\/p>\n\n\n\n<p><strong>\u5173\u4e8e\u541b\u5723\u6cf0<\/strong><\/p>\n\n\n\n<p>\u541b\u5723\u6cf0\u662f\u4e00\u5bb6\u5168\u7403\u4e00\u4f53\u5316\u7684\u4e34\u5e8a\u9636\u6bb5\u751f\u7269\u6280\u672f\u516c\u53f8\uff0c\u9762\u5411\u4ee3\u8c22\u6027\u75be\u75c5\u3001\u6d88\u5316\u7cfb\u7edf\u75be\u75c5\u7b49\u9886\u57df\u7684\u91cd\u5927\u672a\u6ee1\u8db3\u4e34\u5e8a\u9700\u6c42\uff0c\u7acb\u8db3\u6e90\u5934\u521b\u65b0\uff0c\u4ee5\u60a3\u8005\u7684\u7efc\u5408\u4e34\u5e8a\u83b7\u76ca\u548c\u6574\u4f53\u5065\u5eb7\u6539\u5584\u4e3a\u76ee\u6807\uff0c\u4ee5\u201c\u591a\u901a\u8def\u534f\u540c\u7597\u6cd5\u201d\u4e3a\u7814\u53d1\u7b56\u7565\uff0c\u901a\u8fc7\u56fd\u9645\u591a\u4e2d\u5fc3\u4e34\u5e8a\u8bd5\u9a8c\uff08MRCT\uff09\u540c\u6b65\u5f00\u53d1\u201cFirst-in-Class\u201d\u539f\u521b\u65b0\u836f\u3002<\/p>\n\n\n\n<p>\u516c\u53f8\u62e5\u6709\u4e30\u5bcc\u7684\u4ea7\u54c1\u7ba1\u7ebf\u548c\u4e16\u754c\u4e00\u6d41\u7684\u7814\u53d1\u56e2\u961f\u3002\u5728\u7814\u9879\u76ee\u4e0d\u4ec5\u56ca\u62ec\u539f\u53d1\u6027\u786c\u5316\u6027\u80c6\u7ba1\u708e\uff08PSC\uff09\u3001\u539f\u53d1\u6027\u80c6\u6c41\u6027\u80c6\u7ba1\u708e\uff08PBC\uff09\u7b49\u7f55\u89c1\u75c5\uff0c\u800c\u4e14\u8986\u76d62\u578b\u7cd6\u5c3f\u75c5\u5408\u5e76\u975e\u9152\u7cbe\u6027\u8102\u80aa\u6027\u809d\u75c5\uff08T2DM+NAFLD\uff09\u3001\u975e\u9152\u7cbe\u6027\u8102\u80aa\u6027\u809d\u708e\u5408\u5e762\u578b\u7cd6\u5c3f\u75c5\uff08NASH+T2DM\uff09\u3001\u9ad8\u7518\u6cb9\u4e09\u916f\u8840\u75c7\uff08HTG\uff09\u7b49\u5927\u75c5\u79cd\u3002\u76ee\u524d\u516c\u53f8\u6b63\u5728\u5168\u7403\u8303\u56f4\u5185\u5feb\u901f\u63a8\u8fdb\u591a\u9879\u4e2d\u3001\u540e\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002<\/p>\n\n\n\n<p>\u6709\u5173\u516c\u53f8\u7684\u66f4\u591a\u4fe1\u606f\uff0c\u656c\u8bf7\u8bbf\u95ee<a href=\"https:\/\/hightidetx.com\/\">https:\/\/hightidetx.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>2022\u5e744\u670828\u65e5\uff0c\u4e2d\u56fd\u6df1\u5733\u3001\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u2014\u2014\u541b\u5723\u6cf0\uff08HighTide Therapeutics I [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[8],"tags":[],"class_list":["post-831","post","type-post","status-publish","format-standard","hentry","category-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>\u541b\u5723\u6cf0HTD1801\u6cbb\u75972\u578b\u7cd6\u5c3f\u75c5\u7684\u4e34\u5e8aII\u671f\u8bd5\u9a8c\u9996\u4f4d\u60a3\u8005\u6210\u529f\u5165\u7ec4 - \u541b\u5723\u6cf0\u533b\u836f<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"zh_HK\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u541b\u5723\u6cf0HTD1801\u6cbb\u75972\u578b\u7cd6\u5c3f\u75c5\u7684\u4e34\u5e8aII\u671f\u8bd5\u9a8c\u9996\u4f4d\u60a3\u8005\u6210\u529f\u5165\u7ec4 - \u541b\u5723\u6cf0\u533b\u836f\" \/>\n<meta property=\"og:description\" content=\"2022\u5e744\u670828\u65e5\uff0c\u4e2d\u56fd\u6df1\u5733\u3001\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u2014\u2014\u541b\u5723\u6cf0\uff08HighTide Therapeutics I [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.hightidetx.com\/cn\/2022\/04\/28\/hightide-therapeutics-announces-first-patient-dosed-in-phase-2-clinical-study-evaluating-htd1801-in-type-2-diabetes-mellitus\/\" \/>\n<meta property=\"og:site_name\" content=\"\u541b\u5723\u6cf0\u533b\u836f\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/hightidethera\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-04-28T22:47:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-24T08:38:52+00:00\" \/>\n<meta name=\"author\" content=\"webmaster\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@HighTideThera\" \/>\n<meta name=\"twitter:site\" content=\"@HighTideThera\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"webmaster\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9810\u8a08\u95b1\u8b80\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 \u5206\u9418\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.hightidetx.com\/cn\/2022\/04\/28\/hightide-therapeutics-announces-first-patient-dosed-in-phase-2-clinical-study-evaluating-htd1801-in-type-2-diabetes-mellitus\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.hightidetx.com\/cn\/2022\/04\/28\/hightide-therapeutics-announces-first-patient-dosed-in-phase-2-clinical-study-evaluating-htd1801-in-type-2-diabetes-mellitus\/\"},\"author\":{\"name\":\"webmaster\",\"@id\":\"https:\/\/www.hightidetx.com\/cn\/#\/schema\/person\/75dbe1608d86bf00d912abe7ddd01455\"},\"headline\":\"\u541b\u5723\u6cf0HTD1801\u6cbb\u75972\u578b\u7cd6\u5c3f\u75c5\u7684\u4e34\u5e8aII\u671f\u8bd5\u9a8c\u9996\u4f4d\u60a3\u8005\u6210\u529f\u5165\u7ec4\",\"datePublished\":\"2022-04-28T22:47:00+00:00\",\"dateModified\":\"2024-12-24T08:38:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.hightidetx.com\/cn\/2022\/04\/28\/hightide-therapeutics-announces-first-patient-dosed-in-phase-2-clinical-study-evaluating-htd1801-in-type-2-diabetes-mellitus\/\"},\"wordCount\":81,\"publisher\":{\"@id\":\"https:\/\/www.hightidetx.com\/cn\/#organization\"},\"articleSection\":[\"News\"],\"inLanguage\":\"zh-HK\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.hightidetx.com\/cn\/2022\/04\/28\/hightide-therapeutics-announces-first-patient-dosed-in-phase-2-clinical-study-evaluating-htd1801-in-type-2-diabetes-mellitus\/\",\"url\":\"https:\/\/www.hightidetx.com\/cn\/2022\/04\/28\/hightide-therapeutics-announces-first-patient-dosed-in-phase-2-clinical-study-evaluating-htd1801-in-type-2-diabetes-mellitus\/\",\"name\":\"\u541b\u5723\u6cf0HTD1801\u6cbb\u75972\u578b\u7cd6\u5c3f\u75c5\u7684\u4e34\u5e8aII\u671f\u8bd5\u9a8c\u9996\u4f4d\u60a3\u8005\u6210\u529f\u5165\u7ec4 - \u541b\u5723\u6cf0\u533b\u836f\",\"isPartOf\":{\"@id\":\"https:\/\/www.hightidetx.com\/cn\/#website\"},\"datePublished\":\"2022-04-28T22:47:00+00:00\",\"dateModified\":\"2024-12-24T08:38:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.hightidetx.com\/cn\/2022\/04\/28\/hightide-therapeutics-announces-first-patient-dosed-in-phase-2-clinical-study-evaluating-htd1801-in-type-2-diabetes-mellitus\/#breadcrumb\"},\"inLanguage\":\"zh-HK\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.hightidetx.com\/cn\/2022\/04\/28\/hightide-therapeutics-announces-first-patient-dosed-in-phase-2-clinical-study-evaluating-htd1801-in-type-2-diabetes-mellitus\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.hightidetx.com\/cn\/2022\/04\/28\/hightide-therapeutics-announces-first-patient-dosed-in-phase-2-clinical-study-evaluating-htd1801-in-type-2-diabetes-mellitus\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.hightidetx.com\/cn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u541b\u5723\u6cf0HTD1801\u6cbb\u75972\u578b\u7cd6\u5c3f\u75c5\u7684\u4e34\u5e8aII\u671f\u8bd5\u9a8c\u9996\u4f4d\u60a3\u8005\u6210\u529f\u5165\u7ec4\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.hightidetx.com\/cn\/#website\",\"url\":\"https:\/\/www.hightidetx.com\/cn\/\",\"name\":\"\u541b\u5723\u6cf0\u533b\u836f\",\"description\":\"\u60a8\u7684\u5e0c\u671b\uff0c\u6211\u4eec\u7684\u4f7f\u547d\u3002\",\"publisher\":{\"@id\":\"https:\/\/www.hightidetx.com\/cn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.hightidetx.com\/cn\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-HK\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.hightidetx.com\/cn\/#organization\",\"name\":\"\u541b\u5723\u6cf0\u533b\u836f\",\"url\":\"https:\/\/www.hightidetx.com\/cn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-HK\",\"@id\":\"https:\/\/www.hightidetx.com\/cn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/hightidetx.com\/cn\/wp-content\/uploads\/sites\/2\/2024\/12\/hidetide-logo-cn.png\",\"contentUrl\":\"https:\/\/hightidetx.com\/cn\/wp-content\/uploads\/sites\/2\/2024\/12\/hidetide-logo-cn.png\",\"width\":270,\"height\":81,\"caption\":\"\u541b\u5723\u6cf0\u533b\u836f\"},\"image\":{\"@id\":\"https:\/\/www.hightidetx.com\/cn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/hightidethera\/\",\"https:\/\/x.com\/HighTideThera\",\"https:\/\/www.linkedin.com\/company\/hightide-therapeutics\/posts\/?feedView=all\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.hightidetx.com\/cn\/#\/schema\/person\/75dbe1608d86bf00d912abe7ddd01455\",\"name\":\"webmaster\",\"url\":\"https:\/\/www.hightidetx.com\/cn\/author\/webmaster\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u541b\u5723\u6cf0HTD1801\u6cbb\u75972\u578b\u7cd6\u5c3f\u75c5\u7684\u4e34\u5e8aII\u671f\u8bd5\u9a8c\u9996\u4f4d\u60a3\u8005\u6210\u529f\u5165\u7ec4 - \u541b\u5723\u6cf0\u533b\u836f","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"zh_HK","og_type":"article","og_title":"\u541b\u5723\u6cf0HTD1801\u6cbb\u75972\u578b\u7cd6\u5c3f\u75c5\u7684\u4e34\u5e8aII\u671f\u8bd5\u9a8c\u9996\u4f4d\u60a3\u8005\u6210\u529f\u5165\u7ec4 - \u541b\u5723\u6cf0\u533b\u836f","og_description":"2022\u5e744\u670828\u65e5\uff0c\u4e2d\u56fd\u6df1\u5733\u3001\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u2014\u2014\u541b\u5723\u6cf0\uff08HighTide Therapeutics I [&hellip;]","og_url":"https:\/\/www.hightidetx.com\/cn\/2022\/04\/28\/hightide-therapeutics-announces-first-patient-dosed-in-phase-2-clinical-study-evaluating-htd1801-in-type-2-diabetes-mellitus\/","og_site_name":"\u541b\u5723\u6cf0\u533b\u836f","article_publisher":"https:\/\/www.facebook.com\/hightidethera\/","article_published_time":"2022-04-28T22:47:00+00:00","article_modified_time":"2024-12-24T08:38:52+00:00","author":"webmaster","twitter_card":"summary_large_image","twitter_creator":"@HighTideThera","twitter_site":"@HighTideThera","twitter_misc":{"\u4f5c\u8005":"webmaster","\u9810\u8a08\u95b1\u8b80\u6642\u9593":"2 \u5206\u9418"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.hightidetx.com\/cn\/2022\/04\/28\/hightide-therapeutics-announces-first-patient-dosed-in-phase-2-clinical-study-evaluating-htd1801-in-type-2-diabetes-mellitus\/#article","isPartOf":{"@id":"https:\/\/www.hightidetx.com\/cn\/2022\/04\/28\/hightide-therapeutics-announces-first-patient-dosed-in-phase-2-clinical-study-evaluating-htd1801-in-type-2-diabetes-mellitus\/"},"author":{"name":"webmaster","@id":"https:\/\/www.hightidetx.com\/cn\/#\/schema\/person\/75dbe1608d86bf00d912abe7ddd01455"},"headline":"\u541b\u5723\u6cf0HTD1801\u6cbb\u75972\u578b\u7cd6\u5c3f\u75c5\u7684\u4e34\u5e8aII\u671f\u8bd5\u9a8c\u9996\u4f4d\u60a3\u8005\u6210\u529f\u5165\u7ec4","datePublished":"2022-04-28T22:47:00+00:00","dateModified":"2024-12-24T08:38:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.hightidetx.com\/cn\/2022\/04\/28\/hightide-therapeutics-announces-first-patient-dosed-in-phase-2-clinical-study-evaluating-htd1801-in-type-2-diabetes-mellitus\/"},"wordCount":81,"publisher":{"@id":"https:\/\/www.hightidetx.com\/cn\/#organization"},"articleSection":["News"],"inLanguage":"zh-HK"},{"@type":"WebPage","@id":"https:\/\/www.hightidetx.com\/cn\/2022\/04\/28\/hightide-therapeutics-announces-first-patient-dosed-in-phase-2-clinical-study-evaluating-htd1801-in-type-2-diabetes-mellitus\/","url":"https:\/\/www.hightidetx.com\/cn\/2022\/04\/28\/hightide-therapeutics-announces-first-patient-dosed-in-phase-2-clinical-study-evaluating-htd1801-in-type-2-diabetes-mellitus\/","name":"\u541b\u5723\u6cf0HTD1801\u6cbb\u75972\u578b\u7cd6\u5c3f\u75c5\u7684\u4e34\u5e8aII\u671f\u8bd5\u9a8c\u9996\u4f4d\u60a3\u8005\u6210\u529f\u5165\u7ec4 - \u541b\u5723\u6cf0\u533b\u836f","isPartOf":{"@id":"https:\/\/www.hightidetx.com\/cn\/#website"},"datePublished":"2022-04-28T22:47:00+00:00","dateModified":"2024-12-24T08:38:52+00:00","breadcrumb":{"@id":"https:\/\/www.hightidetx.com\/cn\/2022\/04\/28\/hightide-therapeutics-announces-first-patient-dosed-in-phase-2-clinical-study-evaluating-htd1801-in-type-2-diabetes-mellitus\/#breadcrumb"},"inLanguage":"zh-HK","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.hightidetx.com\/cn\/2022\/04\/28\/hightide-therapeutics-announces-first-patient-dosed-in-phase-2-clinical-study-evaluating-htd1801-in-type-2-diabetes-mellitus\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.hightidetx.com\/cn\/2022\/04\/28\/hightide-therapeutics-announces-first-patient-dosed-in-phase-2-clinical-study-evaluating-htd1801-in-type-2-diabetes-mellitus\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.hightidetx.com\/cn\/"},{"@type":"ListItem","position":2,"name":"\u541b\u5723\u6cf0HTD1801\u6cbb\u75972\u578b\u7cd6\u5c3f\u75c5\u7684\u4e34\u5e8aII\u671f\u8bd5\u9a8c\u9996\u4f4d\u60a3\u8005\u6210\u529f\u5165\u7ec4"}]},{"@type":"WebSite","@id":"https:\/\/www.hightidetx.com\/cn\/#website","url":"https:\/\/www.hightidetx.com\/cn\/","name":"\u541b\u5723\u6cf0\u533b\u836f","description":"\u60a8\u7684\u5e0c\u671b\uff0c\u6211\u4eec\u7684\u4f7f\u547d\u3002","publisher":{"@id":"https:\/\/www.hightidetx.com\/cn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.hightidetx.com\/cn\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-HK"},{"@type":"Organization","@id":"https:\/\/www.hightidetx.com\/cn\/#organization","name":"\u541b\u5723\u6cf0\u533b\u836f","url":"https:\/\/www.hightidetx.com\/cn\/","logo":{"@type":"ImageObject","inLanguage":"zh-HK","@id":"https:\/\/www.hightidetx.com\/cn\/#\/schema\/logo\/image\/","url":"https:\/\/hightidetx.com\/cn\/wp-content\/uploads\/sites\/2\/2024\/12\/hidetide-logo-cn.png","contentUrl":"https:\/\/hightidetx.com\/cn\/wp-content\/uploads\/sites\/2\/2024\/12\/hidetide-logo-cn.png","width":270,"height":81,"caption":"\u541b\u5723\u6cf0\u533b\u836f"},"image":{"@id":"https:\/\/www.hightidetx.com\/cn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/hightidethera\/","https:\/\/x.com\/HighTideThera","https:\/\/www.linkedin.com\/company\/hightide-therapeutics\/posts\/?feedView=all"]},{"@type":"Person","@id":"https:\/\/www.hightidetx.com\/cn\/#\/schema\/person\/75dbe1608d86bf00d912abe7ddd01455","name":"webmaster","url":"https:\/\/www.hightidetx.com\/cn\/author\/webmaster\/"}]}},"_links":{"self":[{"href":"https:\/\/www.hightidetx.com\/cn\/wp-json\/wp\/v2\/posts\/831","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hightidetx.com\/cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hightidetx.com\/cn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hightidetx.com\/cn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hightidetx.com\/cn\/wp-json\/wp\/v2\/comments?post=831"}],"version-history":[{"count":0,"href":"https:\/\/www.hightidetx.com\/cn\/wp-json\/wp\/v2\/posts\/831\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hightidetx.com\/cn\/wp-json\/wp\/v2\/media?parent=831"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hightidetx.com\/cn\/wp-json\/wp\/v2\/categories?post=831"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hightidetx.com\/cn\/wp-json\/wp\/v2\/tags?post=831"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}